Author of

• 25890

  +

  OA10 - Right Patient, Right Target & Right Drug - Novel Treatments and Research Partnerships (ID 910)

  • Event: WCLC 2018
  • Type: Oral Abstract Session
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 10:30 - 12:00, Room 106

  • 25894

    +

    OA10.05 - An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09) (ID 14365)

    11:15 - 11:25  |  Author(s): Hyun Woo Lee
    • Abstract
    • Presentation
    • Slides

    Background
    

    Approximately 10% of EGFR mutants harbor uncommon mutations, which represent a heterogeneous group of rare molecular alterations within exons 18-21 and the sensitivity to EGFR TKIs is variable. Osimertinib is a potent irreversible inhibitor of both sensitizing EGFR mutation and T790M. In preclinical data, osimertinib was found to be active against most uncommon EGFR mutants, apart from the exon 20 insertion variant. Here we present the efficacy and safety of osimertinib in patients with uncommon EGFR mutation positive NSCLC.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Patients with histologically confirmed metastatic or recurrent NSCLC with activating EGFR mutation other than exon 19 deletion, L858R, T790M and insertion in exon 20 were eligible. Patients received 80mg of osimertinib orally, once daily until progression or unacceptable toxicity. Response was assessed every 8 weeks by investigator. The trial was registered with ClinicalTrials.gov, number NCT03424759.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Between Mar 2016 and Oct 2017, 35 patients were enrolled. Median age was 59, 63% male, 43% never smoker, 97% adenocarcinoma. 63% of patients were treated as first-line therapy. The mutations identified were G719A/C/D/S/X (19, 54.3%) followed by L861Q (9, 25.7%), S7681 (8, 22.9%), and others (3, 8.6%). The overall response rate was 50.0% (95% CI 32.8-67.2) and DCR was 88.9% (95% CI 78.1-99.7). Seven patients (77.8%) with L861Q mutation achieved partial response; 10/19 (52.6%) with G719A/C/D/S/X mutation; 3/8 (37.5%) with S768I mutation. At data cutoff (Apr, 2018), the median PFS was 8.2 months (95% CI 1.9- 14.4) and median duration of response was 9.8 months (95% CI 7.6-12.0). The most common adverse events were rash (n=11, 31.4%), anorexia (n=8, 22.9%), and diarrhea (n=7, 20.0%). Grade 3 or 4 AEs were reported in 8 of 35 patients (23%), but all of AEs were manageable.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Osimertinib showed highly active in NSCLC patients harboring uncommon EGFR mutation with manageable safety profile, consistent with previous reports. Further analysis will be provided.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

• 25935

  +

  P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26681

    +

    P1.15-14 - Pneumonia in Patients with Lung Cancer of South Korea: A Nationwide Population Based Study (ID 13597)

    16:45 - 18:00  |  Presenting Author(s): Hyun Woo Lee
    • Abstract
    • Slides

    Background
    

    We analyzed the prevalence of pneumonia in lung cancer survivors using claims data from the Health Insurance Review and Assessment Service (HIRA) in South Korea.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We defined pneumonia among a nationwide cohort of 173,390 patients who were diagnosed with lung cancer and underwent surgery from January 1, 2010 to December 31, 2014, based on HIRA claim data. Descriptive statistics were calculated to estimate the frequency of pneumonia using diagnostic code and utilization pattern at medical institutions.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Thirty two thousand five hundred lung cancer survivors (19.8%) were diagnosed with pneumonia. The overall frequency of influenza increased from February (n=8089) and peaked in May (n=9,654). Over 59.06% (57,979) of claims for pneumonia treatment were in the clinic, whereas general hospitals accounted for 40.94% (40,184). Among 101,351 claims, admission rate increased as patients get older and the average length of hospitalization was 4.8 days. Elderly breast cancer survivors over 70 years old had the longest length of hospitalization at 6.2 days.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Lung cancer survivors are more susceptible to pneumonia than non-cancer survivors. It is important not only to raise the vaccination rate among young cancer survivors, but also to quickly identify symptoms and begin treatment for pneumonia in elderly cancer survivors.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.